TherapeuticsMD (TXMD) Accounts Payables (2010 - 2026)

TherapeuticsMD has reported Accounts Payables for 17 years, with the latest figure at $15000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 91.48% year-over-year to $15000.0; the trailing twelve-month figure through Mar 2026 stood at $15000.0 (down 91.48% YoY), and the FY2025 full-year result was $377000.0, up 46.12% from the prior year.
• Accounts Payables for Q1 2026 stood at $15000.0, down from $377000.0 in the prior quarter.
• The five-year high for Accounts Payables was $20.8 million in Q1 2022, with the low at $15000.0 in Q1 2026.
• Historically, Accounts Payables has averaged $3.7 million across 5 years, with a median of $1.5 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 98.75% — and 2025, when it soared 1011.89%.
• TherapeuticsMD's Accounts Payables stood at $2.2 million in 2022, then plunged by 98.75% to $27000.0 in 2023, then jumped by 855.56% to $258000.0 in 2024, then surged by 46.12% to $377000.0 in 2025, then sank by 96.02% to $15000.0 in 2026.
• The last three Accounts Payables figures came in at $15000.0 (Q1 2026), $377000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.